# Safety and Efficacy of FAP iCDC in Ischemia Cardiomyopathy

> **NCT07505199** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 15 (estimated)

## Conditions studied

- Ischemic Cardiomyopathy
- Cell Therapy

## Interventions

- **BIOLOGICAL:** autologus FAP-targeted immunosuppressive CAR-DCs (iCDC)

## Key facts

- **NCT ID:** NCT07505199
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505199, "Safety and Efficacy of FAP iCDC in Ischemia Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07505199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*